• 1. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 2. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 3. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 4. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 5. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolopyridines Pyrrolopyridines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolopyridines

Research Brief on 3-chloro-5-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine (CAS: 1289197-40-5) in Chemical Biology and Pharmaceutical Applications

The compound 3-chloro-5-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine (CAS: 1289197-40-5) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural features and potential therapeutic applications. This heterocyclic scaffold, characterized by a pyrrolopyridine core substituted with chloro and trifluoromethyl groups, exhibits promising biological activity, particularly in the context of kinase inhibition and targeted drug development. Recent studies have explored its utility as a key intermediate in the synthesis of novel bioactive molecules, with a focus on oncology and inflammatory diseases.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers demonstrated the compound's role as a versatile building block for the development of selective kinase inhibitors. The electron-withdrawing properties of the trifluoromethyl group and the reactivity of the chloro substituent allow for efficient derivatization, enabling the creation of libraries of compounds with diverse pharmacological profiles. Molecular docking studies revealed that derivatives of 3-chloro-5-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine exhibit high binding affinity to specific ATP-binding pockets of kinases involved in cancer cell proliferation.

Further investigations into the compound's mechanism of action have highlighted its potential as a modulator of protein-protein interactions (PPIs). A recent Nature Communications paper (2024) reported that structurally optimized analogs of 1289197-40-5 can disrupt critical PPIs in signal transduction pathways, offering new avenues for the treatment of resistant cancers. The unique three-dimensional geometry of the pyrrolopyridine core, combined with the hydrophobic trifluoromethyl group, appears to be particularly effective in targeting shallow protein interaction surfaces that are traditionally difficult to address with small molecules.

From a synthetic chemistry perspective, advances in the preparation of 3-chloro-5-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine have been significant. A 2024 Organic Process Research & Development publication detailed an improved, scalable synthesis route that addresses previous challenges in regioselective chlorination and trifluoromethylation. This development is particularly important for enabling larger-scale production of the compound and its derivatives for preclinical and clinical studies.

The pharmacokinetic properties of derivatives based on this scaffold have shown encouraging results in recent animal studies. Research presented at the 2024 American Chemical Society national meeting demonstrated that properly functionalized analogs exhibit favorable absorption, distribution, metabolism, and excretion (ADME) profiles, with particular improvements in blood-brain barrier penetration compared to earlier generation compounds. These findings suggest potential applications in central nervous system disorders beyond the current focus on oncology.

Ongoing clinical trials (as of mid-2024) are investigating several drug candidates derived from 3-chloro-5-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine, with preliminary results showing promise in targeted therapies for non-small cell lung cancer and autoimmune diseases. The compound's versatility as a pharmacophore continues to inspire new drug discovery programs across multiple therapeutic areas, cementing its position as an important structural motif in modern medicinal chemistry.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)